Company Description
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally.
The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables.
The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications.
In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software.
Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007.
The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 15, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 193 |
| CEO | Robert G. Spignesi Jr. |
Contact Details
Address: 1001 Pawtucket Blvd. Lowell, Massachusetts 01854 United States | |
| Phone | 978-349-3200 |
| Website | rapidmicrobio.com |
Stock Details
| Ticker Symbol | RPID |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001380106 |
| CUSIP Number | 75340L104 |
| ISIN Number | US75340L1044 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Robert G. Spignesi Jr. | Chief Executive Officer, President and Director |
| Sean M. Wirtjes | Chief Financial Officer |
| John J. Addington Wilson | Chief Operating Officer |
| Michael Beaulieu C.F.A. | Vice President of Investor Relations and Corporate Communications |
| Michael Wysocki | Senior Vice President of Sales and Marketing |
| Victoria L. Vezina | Chief Human Resources Officer |
| Kristine Williams | Senior Vice President of Research and Development and Product Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | ARS | Filing |
| Apr 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 1, 2024 | 10-K | Annual Report |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | 8-K | Current Report |
| Jan 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |